GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Cash Conversion Cycle

OptiNose (OptiNose) Cash Conversion Cycle : 570.57 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is OptiNose Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

OptiNose's Days Sales Outstanding for the three months ended in Mar. 2024 was 104.72.
OptiNose's Days Inventory for the three months ended in Mar. 2024 was 680.74.
OptiNose's Days Payable for the three months ended in Mar. 2024 was 214.89.
Therefore, OptiNose's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 570.57.


OptiNose Cash Conversion Cycle Historical Data

The historical data trend for OptiNose's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Cash Conversion Cycle Chart

OptiNose Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only 79.77 220.43 291.17 323.34 314.30

OptiNose Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 362.19 150.44 188.03 249.07 570.57

Competitive Comparison of OptiNose's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptiNose's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where OptiNose's Cash Conversion Cycle falls into.



OptiNose Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

OptiNose's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=138.46+369.84-194
=314.30

OptiNose's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=104.72+680.74-214.89
=570.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OptiNose  (NAS:OPTN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


OptiNose Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of OptiNose's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


OptiNose (OptiNose) Business Description

Traded in Other Exchanges
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Executives
Marino Michael F Iii officer: Chief Legal Officer & Corp Sec C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud officer: President & COO 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller director, officer: Chief Executive Officer C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis officer: Acting Chief Financial Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli officer: Chief Commercial Officer 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence officer: Chief Commercial Officer 1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick officer: Chief Accounting Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080

OptiNose (OptiNose) Headlines

From GuruFocus

Optinose Announces Departure of Chief Financial Officer

By PurpleRose PurpleRose 07-13-2022

Optinose Announces Departure of Acting Chief Financial Officer

By Value_Insider Value_Insider 12-09-2022

Optinose Announces CEO Transition and Business Update

By Stock market mentor Stock market mentor 01-31-2023

Insider Alert: An Insider Just Sold OptiNose Inc Shares

By GuruFocus Research GuruFocus Editor 12-20-2022

Optinose Announces Proposed Public Offering of Common Stock and Warrants

By Value_Insider Value_Insider 11-21-2022